(E)-N-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (E)-N-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide
• 英文别名: (8S,9S,10R,13R,14S,17R)-N,10,13-trimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-imine oxide
• 化学式: C₂₈H₄₇NO
• 分子量: 413.687
• InChiKey: HGVZAIPGWNYAPW-BARRXVKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  28.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-胆甾烯-3-酮 、 N-甲基羟胺盐酸盐 在 sodium sulfate 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 (E)-N-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide 、 (Z)-N-((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide
  参考文献：
  名称：

  STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS

  摘要：

  这项发明涉及神经保护、抗氧化的类固醇亚硝酮，其对血脑屏障有很高的渗透性，作为治疗脑卒中或缺血、阿尔茨海默病、帕金森病和肌萎缩侧索硬化症的潜在药物。

  公开号：

  US20160089382A1

文献信息

• STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

  公开号：US20160089382A1

  公开（公告）日：2016-03-31

  The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis.

  这项发明涉及神经保护、抗氧化的类固醇亚硝酮，其对血脑屏障有很高的渗透性，作为治疗脑卒中或缺血、阿尔茨海默病、帕金森病和肌萎缩侧索硬化症的潜在药物。
• STEROIDAL NITRONE FOR THE TREATMENT AND/OR PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA
  申请人：Isquaemia Biotech, S.L.

  公开号：EP3875095A1

  公开（公告）日：2021-09-08

  The present invention refers to Steroidal nitrone (E)-N- ((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-7,8,9,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide (F2), as well as any pharmaceutically acceptable salt thereof, for use in promoting neuroprotection in a subject in need thereof by increasing SOD1 expression, wherein such subject is suffering from a disease selected from the list consisting of permanent cerebral ischemia or transitory cerebral ischemia.

  本发明涉及甾体腈酮(E)-N-((8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-((R)-6-甲基庚-2-基)-7,8,9,11,12,13,14,15、16,17-十氢-1H-环戊并[a]菲-3(2H,6H,10H)-亚基)甲胺氧化物(F2)及其任何药学上可接受的盐、用于通过增加SOD1的表达促进有需要的受试者的神经保护，其中该受试者患有选自永久性脑缺血或暂时性脑缺血的疾病。
• Steroidal nitrones for the treatment and prevention of a cerebral stroke or ischaemia, alzheimer and parkinson disease and amyotrophic lateral sclerosis
  申请人：FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

  公开号：US10071106B2

  公开（公告）日：2018-09-11

  The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis.

  本发明涉及具有神经保护作用的抗氧化甾体硝基化合物，血脑屏障对其具有高渗透性，可作为治疗脑中风或脑缺血、阿尔茨海默病、帕金森病和肌萎缩性脊髓侧索硬化症的潜在药物。
• [EN] STEROIDAL NITRONE F2 FOR USE IN THE PREVENTION AND/OR TREATMENT OF PERMANENT CEREBRAL ISCHAEMIA<br/>[FR] NITRONE F2 STÉROÏDIENNE DESTINÉE À ÊTRE UTILISÉE DANS LA PRÉVENTION ET/OU LE TRAITEMENT DE L'ISCHÉMIE CÉRÉBRALE PERMANENTE
  申请人：ISQUAEMIA BIOTECH S L

  公开号：WO2021176085A1

  公开（公告）日：2021-09-10

  The present invention refers to steroidal nitrone (E)-N-((8S,9S,10R,13R,14S,17R)-10,13-di methyl-17-( (R)-6-methyl hepta n-2-yl)-7,8,9,l1,12,13,14,15,16,17-deca hydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide (F2), as well as any pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of permanent cerebral ischemia.
• CholesteroNitrones for Stroke
  作者：Maria I. Ayuso、Mourad Chioua、Emma Martínez-Alonso、Elena Soriano、Joan Montaner、Jaime Masjuán、Dimitra J. Hadjipavlou-Litina、José Marco-Contelles、Alberto Alcázar

  DOI：10.1021/acs.jmedchem.5b00755

  日期：2015.8.27

  This study describes CholesteroNitrone 2 as an antioxidant and neuroprotective agent against ischemic injury. Neuroprotection was assessed using in vitro and in vivo experimental ischemia models. The compound significantly increased cell viability, induced neuroprotection following ischemic reperfusion, and decreased neurological deficit scores in treated animals, supporting the next preclinical studies as a potential agent for the treatment of stroke.